Jeffrey N. Miner

5.8k total citations · 1 hit paper
71 papers, 4.7k citations indexed

About

Jeffrey N. Miner is a scholar working on Nephrology, Molecular Biology and Genetics. According to data from OpenAlex, Jeffrey N. Miner has authored 71 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Nephrology, 26 papers in Molecular Biology and 25 papers in Genetics. Recurrent topics in Jeffrey N. Miner's work include Gout, Hyperuricemia, Uric Acid (27 papers), Estrogen and related hormone effects (24 papers) and Hormonal Regulation and Hypertension (10 papers). Jeffrey N. Miner is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (27 papers), Estrogen and related hormone effects (24 papers) and Hormonal Regulation and Hypertension (10 papers). Jeffrey N. Miner collaborates with scholars based in United States, United Kingdom and New Zealand. Jeffrey N. Miner's co-authors include Keith R. Yamamoto, Marc I. Diamond, Steven K. Yoshinaga, Sha Liu, Philip K. Tan, Jonathan Rosen, John A. Mitchell, D K Granner, Enyu Imai and David Hyndman and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jeffrey N. Miner

69 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transcription Factor Interactions: Selectors of Positive or Negative Regulation from a Single DNA Element

1990 1.2k citations Marc I. Diamond, Jeffrey N. Miner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey N. Miner United States	35	2.1k	1.5k	972	894	603	71	4.7k
Robert A. Orlando United States	38	1.7k 0.8×	433 0.3×	182 0.2×	770 0.9×	353 0.6×	80	4.1k
Norie Araki Japan	36	2.1k 1.0×	224 0.1×	654 0.7×	240 0.3×	486 0.8×	102	4.6k
Chieko Mineo United States	44	3.6k 1.7×	1.3k 0.8×	1.3k 1.3×	120 0.1×	680 1.1×	106	7.7k
Kouichi Inukai Japan	41	3.1k 1.5×	440 0.3×	974 1.0×	145 0.2×	289 0.5×	99	5.6k
Reidar Wallin United States	40	1.6k 0.8×	343 0.2×	483 0.5×	431 0.5×	177 0.3×	100	4.0k
Svend O. Freytag United States	41	3.3k 1.6×	2.4k 1.6×	196 0.2×	139 0.2×	1.6k 2.6×	83	5.4k
Mark J. Evans United States	32	1.5k 0.8×	488 0.3×	233 0.2×	118 0.1×	702 1.2×	79	3.2k
Arthur Sands United States	35	4.0k 2.0×	1.1k 0.7×	1.1k 1.2×	72 0.1×	2.1k 3.5×	62	6.5k
Rebecca P. Hughey United States	37	3.5k 1.7×	231 0.2×	434 0.4×	291 0.3×	223 0.4×	94	4.5k
Andrey Sorokin United States	35	2.0k 1.0×	314 0.2×	186 0.2×	232 0.3×	585 1.0×	94	3.5k

Countries citing papers authored by Jeffrey N. Miner

Since Specialization

Citations

This map shows the geographic impact of Jeffrey N. Miner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey N. Miner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey N. Miner more than expected).

Fields of papers citing papers by Jeffrey N. Miner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey N. Miner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey N. Miner. The network helps show where Jeffrey N. Miner may publish in the future.

Co-authorship network of co-authors of Jeffrey N. Miner

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey N. Miner. A scholar is included among the top collaborators of Jeffrey N. Miner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey N. Miner. Jeffrey N. Miner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenthal, Sara Brin, et al.. (2023). Role of Hepatic Stellate and Liver Sinusoidal Endothelial Cells in a Human Primary Cell Three-Dimensional Model of Nonalcoholic Steatohepatitis. American Journal Of Pathology. 194(3). 353–368. 5 indexed citations

Merriman, Tony R., Murray Cadzow, Marilyn E. Merriman, et al.. (2019). A genome-wide association study of gout in people of European ancestry. Figshare. 69.

McKinney, Cushla, Tanya J. Major, Lisa K. Stamp, et al.. (2018). The relationship between ferritin and urate levels and risk of gout. Arthritis Research & Therapy. 20(1). 179–179. 31 indexed citations

Yang, Chun, Zancong Shen, David M. Wilson, et al.. (2018). Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. Drug Metabolism and Disposition. 47(2). 104–113. 8 indexed citations

Iverson, Cory, Sha Liu, Scott Baumgartner, et al.. (2018). Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation. Scientific Reports. 8(1). 1217–1217. 24 indexed citations

Roberts, Rebecca L, Jeffrey N. Miner, Nicola Dalbeth, et al.. (2017). Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Lara D. Veeken. 57(4). 656–660. 40 indexed citations

Hyndman, David, Sha Liu, & Jeffrey N. Miner. (2016). Urate Handling in the Human Body. Current Rheumatology Reports. 18(6). 34–34. 122 indexed citations

Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2015). A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research. 22(10). 2368–2376. 16 indexed citations

Ives, Annette, Johji Nomura, Fabio Martinon, et al.. (2015). Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. Nature Communications. 6(1). 6555–6555. 207 indexed citations

10.

Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations

11.

Schmieder, Roberta, Florian Puehler, Roland Neuhaus, et al.. (2013). Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma. Neoplasia. 15(10). 1161–IN24. 51 indexed citations

12.

Chapman, Mark S. & Jeffrey N. Miner. (2011). Novel mitogen-activated protein kinase kinase inhibitors. Expert Opinion on Investigational Drugs. 20(2). 209–220. 29 indexed citations

13.

Chapman, Mark S., et al.. (2010). Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer. 10(1). 515–515. 28 indexed citations

14.

Iverson, Cory, Gary Larson, Chon Lai, et al.. (2009). RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer. Cancer Research. 69(17). 6839–6847. 153 indexed citations

15.

Schaufele, Fred, et al.. (2005). The structural basis of androgen receptor activation: Intramolecular and intermolecular amino–carboxy interactions. Proceedings of the National Academy of Sciences. 102(28). 9802–9807. 161 indexed citations

16.

Miner, Jeffrey N., Mei Hong, & A. Negro‐Vilar. (2005). New and improved glucocorticoid receptor ligands. Expert Opinion on Investigational Drugs. 14(12). 1527–1545. 53 indexed citations

17.

Elmore, Steven W., John K. Pratt, Michael J. Coghlan, et al.. (2004). Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorganic & Medicinal Chemistry Letters. 14(7). 1721–1727. 41 indexed citations

18.

Coghlan, Michael J., Philip R. Kym, Steven W. Elmore, et al.. (2001). Synthesis and Characterization of Non-Steroidal Ligands for the Glucocorticoid Receptor: Selective Quinoline Derivatives with Prednisolone-Equivalent Functional Activity. Journal of Medicinal Chemistry. 44(18). 2879–2885. 78 indexed citations

19.

Imai, Enyu, Jeffrey N. Miner, John A. Mitchell, Keith R. Yamamoto, & D K Granner. (1993). Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids.. Journal of Biological Chemistry. 268(8). 5353–5356. 261 indexed citations

20.

Yamamoto, Keith R., et al.. (1992). 43 Combinatorial Regulation at a Mammalian Composite Response Element. Cold Spring Harbor Monograph Archive. 1169–1192. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact